Labanimal

The March 2020 episode of 3 Minute 3Rs, brought to you by the NC3Rs (www.nc3rs.org.uk), the North American 3Rs Collaborative (www.na3rsc.org), and Lab Animal (www.nature.com/laban) The papers: 1. https://pubmed.ncbi.nlm.nih.gov/32076633 2. https://www.sciencedirect.com/science/article/pii/S0273230020300507 3. https://www.nature.com/articles/s41598-020-59012-4 Transcript [NC3Rs] Nanomedicines have many potential advantages, including their ability to home to specific diseased tissues and exert a localised effect. Due to their relatively large size, the biodistribution of nanomedicines does not follow the same rules as small molecules and is largely dictated by the diameter of the blood vessels they pass through en route to their target tissue. This means that although current methods to assess biodistribution rely heavily on the use of animals including rodents and non-human primates, the results can vary greatly between preclinical species and man. Using an in vitro cell based model of nanoparticle uptake